Galderma Group AG
🇨🇭Switzerland
Restylane Perlane to Shape the Nasal Dorsum and/or Nasal Root
Not Applicable
Completed
- Conditions
- Nasal Augmentation
- Interventions
- Device: Restylane Perlane
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 132
- Registration Number
- NCT02216851
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: CD5789 (trifarotene)
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 453
- Registration Number
- NCT02189629
- Locations
- 🇭🇺
Galderma Investigational Site, Szolnok, Hungary
🇨🇿Galderma Investigational site, Praha 1, Czechia
Plaque Psoriasis Study in Pediatric Subjects
Phase 4
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: placebo comparator
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 19
- Registration Number
- NCT02186665
- Locations
- 🇧🇪
UCL Saint Luc, Brussel, Belgium
🇩🇪University of Tübingen, Tubingen, Germany
🇺🇸Dermatology and Laser Center of Charleston, Charleston, South Carolina, United States
A Post Market Evaluation After Treatment of Nasolabial Folds
Not Applicable
Completed
- Conditions
- Nasolabial Folds
- Interventions
- Device: Restylane
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 114
- Registration Number
- NCT02179736
- Locations
- 🇨🇳
Plastic Surgery InstituteNo, No. 33 Badachu Road, Shijingshan District, Beijing, China
Dose-Escalation of Botulinum Toxin in Subjects With Osteoarthritis of the Knee
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 22
- Registration Number
- NCT02139319
(Macrolane VR30) in Buttocks Reshaping and contouringCellulite (Macrolane VR30) in Buttocks Reshaping and Contouring
Not Applicable
Completed
- Conditions
- Cellulite of the Buttocks
- Interventions
- Device: Hyaluronic acid injection (Macrolane VRF30)
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 20
- Registration Number
- NCT02127723
- Locations
- 🇧🇷
Dr Hexsel, Porto Alegre, RS, Brazil
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 54
- Registration Number
- NCT02125279
- Locations
- 🇺🇸
Johnson Dermatology, Fort Smith, Arkansas, United States
🇺🇸Advanced Skincare Surgery & Medcenter, Burbank, California, United States
🇺🇸University of South Florida, Tampa, Florida, United States
A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines
Phase 4
Completed
- Conditions
- Glabellar Frown Lines
- Interventions
- Drug: Azzalure
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 62
- Registration Number
- NCT02108158
- Locations
- 🇸🇪
Göteborgs Plastikkirurgiska Center, Gothenburg, Sweden
🇸🇪Anna Neuromuskulär Konsult, Uppsala, Sweden
Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 417
- Registration Number
- NCT02073448
- Locations
- 🇯🇵
Galderma investigational site, Saitama, Japan
Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.
Phase 2
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: CD1579 2.5%Drug: CD1579 5%Drug: Vehicle
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 236
- Registration Number
- NCT02073461
- Locations
- 🇯🇵
Galderma investigational site, Fukuoka, Japan
© Copyright 2025. All Rights Reserved by MedPath